Global Med Technologies(R), Inc. at Forefront Helping Clients Adopt International Blood Labeling Standard
October 11 2006 - 10:00AM
PR Newswire (US)
- Company Continues Leadership Through Software, Services and
Education - DENVER, Oct. 11 /PRNewswire-FirstCall/ -- Wyndgate
Technologies(R), a division of Global Med Technologies(R), Inc.,
(OTC:GLOB) (BULLETIN BOARD: GLOB) is furthering its leadership in
the blood industry by offering expert software and services to help
its clients adopt the international standard for blood component
labeling, known as ISBT 128. (Logo:
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO ) ISBT
128 sets a global standard for blood component labeling and enables
blood products to be managed and shared around the world. The
standard revolutionizes the information contained in a blood
component label, allowing for unique identification of any donation
worldwide. This identification number allows a blood component to
be traced back to its donor of origin regardless of where it may be
transfused. In addition, the labeling standard relays critical
information regarding each blood component in a secure electronic
format to help prevent accidental misuse with blood products from
multiple countries or facilities. In effect, ISBT 128 enables blood
products collected in one location to be safely transfused across
borders, governments and healthcare systems. The impact of this
standard for multinational disaster relief programs, widespread
military operations and building international data stores is
significant. Wyndgate Technologies recognized the potential impact
of the international standard on the blood industry early in its
introduction and has supported the standard in its blood software
products since 1999. The ISBT 128 blood labeling standard has been
gaining attention around the world during the past few years,
although a requirement only recently emerged in the United States
mandating that the standard be adopted. With the new U.S.
requirement, Wyndgate has seen an increased demand for ISBT 128
education and services. In an effort to assist its customers to
adopt the standard, Wyndgate has developed an online educational
series and has begun providing consulting services regarding
implementing the standard. More than 500 individuals have attended
one or more of the online education sessions that the company
presented this year. Wyndgate will continue to offer additional
ISBT 128 education sessions and services. "The ISBT 128 initiative
is a substantial step for patient safety and for allowing blood
products to be shared worldwide," stated Michael I Ruxin, M.D.,
Chairman and CEO of Global Med Technologies. Dr. Ruxin continued,
"This standard has the potential to change the way the U.S. and the
world respond to emergencies, disasters and patients' needs by
increasing access to blood products and the information to use the
products safely. Wyndgate saw a need in the industry and among our
clients for software, education and assistance regarding ISBT 128.
In order to further enhance our leadership role in the blood bank
and hospital transfusion software industry, the company moved
forward to fulfill those needs." About Global Med Technologies,
Inc. Global Med Technologies, Inc. is an international e-Health,
medical information technology company, providing information
management software products and services to the healthcare
industry. Its Wyndgate Technologies division is a leading supplier
of information management systems to U.S. and international blood
centers and hospital transfusion centers. Each year, Wyndgate's
products and services manage more than eight million blood
components, representing over 27% of the U.S. blood supply.
Wyndgate's products are being used in Canada and sub-Saharan
Africa, and are being implemented in the Caribbean. Together, the
SafeTrace Tx(R)* advanced transfusion management system and the
SafeTrace(R) donor management system provide Vein-to-Vein(R)
tracking from donor collection to patient transfusion. For more
information about Global Med's products and services, please call
800-WYNDGATE or visit http://www.globalmedtech.com/,
http://www.peoplemed.com/ and http://www.wyndgate.com/. This news
release may include statements that constitute forward-looking
statements, usually containing the words "believe," "estimate,"
"project," "expects" or similar expressions. These statements are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements inherently involve risks and uncertainties that could
cause actual results to differ materially from the forward-looking
statements. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions
or changes after the date of this news release. * Patent Pending
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO
http://photoarchive.ap.org/ DATASOURCE: Global Med Technologies,
Inc. CONTACT: Michael I. Ruxin, M.D., Global Med Technologies,
Inc., +1-303-238-2000 Web site: http://www.globalmedtech.com/ Web
site: http://www.peoplemed.com/ Web site: http://www.wyndgate.com/
Web site: http://www.globalmedtech.com/
Copyright